10 completed, 3 terminated, 1 withdrawn. 10 Phase 1, 4 Phase 2, 1 Phase 3.
By phase and status
Follow sisunatovir: new trials by email Literature Review of sisunatovir trials Research Report on sisunatovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV Placebo, Active - Respiratory Syncytial Virus Infections Phase 1 Terminated Pfizer 10 2024-02-15 2025-12-30 A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Sisunatovir, Placebo - Respiratory Syncytial Virus Infection Phase 2 / Phase 3 Terminated Pfizer 16 2023-12-08 2025-11-10 A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension - Healthy Phase 1 Completed Pfizer 40 2023-11-03 2025-04-24 A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults. Sisunatovir - Respiratory Syncytial Virus Infection Phase 1 Completed Pfizer 12 2023-11-03 2025-02-24 A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Drug: PF-07923568 - Renal Impairment Phase 1 Completed Pfizer 16 2023-10-30 2024-07-19 A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants. sisunatovir - Healthy Phase 1 Completed Pfizer 25 2023-09-01 2025-05-06 A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. PF-07923568 - Liver Diseases, Hepatic Impairment Phase 1 Completed Pfizer 28 2023-06-07 2025-03-21 A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants. sisunatovir, placebo, moxifloxacin - Healthy Phase 1 Completed Pfizer 43 2023-05-15 2024-12-06 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants sisunatovir, Placebo - Respiratory Syncytial Viruses Phase 1 Completed Pfizer 12 2023-02-08 2024-09-19 Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV RV521 oral tablet, Placebo oral tablet - RSV Infection, Stem Cell Transplant Complications Phase 2 Withdrawn Pfizer 2020-06-15 2023-05-08 A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection. RV521, Placebo - Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection Phase 2 Terminated Pfizer 51 2019-11-13 2024-10-23 Pharmacokinetics and Safety of RV521 Formulations RV521 - Respiratory Syncytial Virus Infections Phase 1 Completed Pfizer 9 2019-08-13 2024-06-07 A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants Itraconazole, Verapamil, Rifampicin - Respiratory Syncytial Virus Infections Phase 1 Completed Pfizer 82 2018-11-07 2024-04-22 A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection RV521, Placebo - Respiratory Syncytial Virus Infections Phase 2 Completed Pfizer 66 2017-07-19 2025-07-31
Conditions studied Respiratory Syncytial Virus Infections (7) · Cough (1) · Liver Diseases (1) · Renal Insufficiency (1) · Respiratory Sounds (1) · Respiratory Tract Infections (1) · Rhinitis (1)
Sponsors Pfizer (14)
Countries United States (5) · United Kingdom (4) · Belgium (3) · China (2) · Japan (2) · Argentina (1) · Canada (1) · Chile (1) · Costa Rica (1) · Hungary (1) · India (1) · Israel (1) · Malaysia (1) · New Zealand (1) · Panama (1)
Results publications PMID 31712214 , PMID 41673909
NIH funding 2023 (4), 2018 (1), 2019 (1)